Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Bone Density"" wg kryterium: Temat


Starter badań:

Tytuł:
Design, Synthesis, and Anti-Osteoporotic Characterization of Arginine N -Glycosylated Teriparatide Analogs via the Silver-catalyzed Solid-Phase Glycosylation Strategy.
Autorzy:
Cong W; School of Medicine, Shanghai University, Shanghai 200444, China.
Shen H; School of Medicine, Shanghai University, Shanghai 200444, China.
Jiang Y; School of Pharmacy, Second Military Medical University, Shanghai 200433, China.; Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China.
Li L; School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Kong X; School of Medicine, Shanghai University, Shanghai 200444, China.
Chen S; School of Medicine, Shanghai University, Shanghai 200444, China.
Hu H; School of Medicine, Shanghai University, Shanghai 200444, China.
Li X; School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Jan 25; Vol. 67 (2), pp. 1360-1369. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Journal Article
MeSH Terms:
Teriparatide*/pharmacology
Teriparatide*/therapeutic use
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Silver/pharmacology ; Glycosylation ; Maltose/pharmacology ; Xylose/pharmacology ; Peptides/pharmacology ; Glucose/pharmacology ; Lactose ; Catalysis ; Bone Density
Czasopismo naukowe
Tytuł:
Exploring epigenetic strategies for the treatment of osteoporosis.
Autorzy:
Yi SJ; Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Lim J; Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Kim K; Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea. .
Pokaż więcej
Źródło:
Molecular biology reports [Mol Biol Rep] 2024 Mar 08; Vol. 51 (1), pp. 398. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Osteoporosis*/drug therapy
Osteoporosis*/genetics
Osteoporosis*/metabolism
Bone Density Conservation Agents*
Fractures, Bone*/genetics
Humans ; Aged ; Bone Density ; Epigenesis, Genetic
Czasopismo naukowe
Tytuł:
Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.
Autorzy:
Kong M; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Gao C; Department of Oncology, Qingdao Municipal Hospital, No. 1, Jiao Zhou Road, Qing'dao, 266000, Shandong Province, China.
Luan X; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Fan C; Department of General Surgery, Ankang Hospital of Shandong Province, No. 1, Ji Dai Road, Ji'ning, 272000, Shandong Province, China.
Hao M; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Jin C; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Zhao J; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Li H; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Zhao J; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Luan J; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China.
Lin Y; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China. .
Li Q; Department of Spine Surgery, Qingdao Municipal Hospital, No. 5, Middle Dong Hai Road, Qing'dao, 266000, Shandong Province, China. .
Pokaż więcej
Źródło:
BMC musculoskeletal disorders [BMC Musculoskelet Disord] 2024 Feb 03; Vol. 25 (1), pp. 109. Date of Electronic Publication: 2024 Feb 03.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*
Osteoporosis*/diagnostic imaging
Osteoporosis*/drug therapy
Gastrointestinal Diseases*
Osteoporosis, Postmenopausal*/diagnostic imaging
Osteoporosis, Postmenopausal*/drug therapy
Humans ; Female ; Teriparatide/therapeutic use ; Teriparatide/pharmacology ; Retrospective Studies ; Postmenopause ; Glucocorticoids/therapeutic use ; Bone Density ; Diphosphonates/therapeutic use ; Lumbar Vertebrae/diagnostic imaging
Czasopismo naukowe
Tytuł:
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.
Autorzy:
Makras P; Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou st, 11525, Athens, Greece. .; Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece. .
Yavropoulou MP; Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou st, 11525, Athens, Greece.; Εndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Polyzos SA; First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Papapoulos SE; Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou st, 11525, Athens, Greece.; Center for Bone Quality, Department of Internal Medicine, Section Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
Georgakopoulou D; Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
Papatheodorou A; Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou st, 11525, Athens, Greece.
Anastasilakis AD; Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2024 Feb; Vol. 35 (2), pp. 365-370. Date of Electronic Publication: 2023 Oct 02.
Typ publikacji:
Journal Article
MeSH Terms:
Osteoporosis, Postmenopausal*/drug therapy
Bone Density Conservation Agents*
Bone Resorption*
Humans ; Female ; Animals ; Mice ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Bone Density
Czasopismo naukowe
Tytuł:
The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
Autorzy:
Ramchand SK; Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA. .
Tsai JN; Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Lee H; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Sassana-Khadka G; Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Jordan M; Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Ryan S; Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Leder BZ; Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2024 Feb; Vol. 35 (2), pp. 255-263. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/adverse effects
Osteoporosis, Postmenopausal*
Female ; Humans ; Alendronate/adverse effects ; Raloxifene Hydrochloride/adverse effects ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Bone Density ; Biomarkers
Czasopismo naukowe
Tytuł:
Efficacy of Osteoporosis Medications in Patients with Type 2 Diabetes.
Autorzy:
Vilaca T; Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, University of Sheffield, Sheffield, UK. .; Metabolic Bone Centre - Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK. .
Eastell R; Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
Pokaż więcej
Źródło:
Current osteoporosis reports [Curr Osteoporos Rep] 2024 Feb; Vol. 22 (1), pp. 1-10. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Fractures, Bone*/epidemiology
Fractures, Bone*/prevention & control
Fractures, Bone*/complications
Osteoporosis*/drug therapy
Osteoporosis*/complications
Bone Density Conservation Agents*/therapeutic use
Aged ; Humans ; Bone and Bones ; Bone Density
Czasopismo naukowe
Tytuł:
A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence.
Autorzy:
Ward LM; Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.; Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
Pokaż więcej
Źródło:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jan 25; Vol. 14, pp. 1266986. Date of Electronic Publication: 2024 Jan 25 (Print Publication: 2023).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Osteoporosis*/therapy
Osteoporosis*/drug therapy
Fractures, Bone*/drug therapy
Bone Density Conservation Agents*/therapeutic use
Humans ; Adolescent ; Child ; Adult ; Bone Density ; Risk Factors
Czasopismo naukowe
Tytuł:
Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis.
Autorzy:
Kim JT; Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji University Hospital, Eulji University School of Medicine, Seoul, Korea.
Kim YM; Division of Nephrology, Department of Internal Medicine, Nowon Eulji University Hospital, Eulji University School of Medicine, Seoul, Korea.
Jung KY; Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji University Hospital, Eulji University School of Medicine, Seoul, Korea.
Choi H; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Lee SY; Division of Nephrology, Department of Internal Medicine, Nowon Eulji University Hospital, Eulji University School of Medicine, Seoul, Korea.
Kim HJ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji University Hospital, Eulji University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
The Korean journal of internal medicine [Korean J Intern Med] 2024 Jan; Vol. 39 (1), pp. 148-159. Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/drug therapy
Renal Insufficiency, Chronic*/complications
Renal Insufficiency, Chronic*/diagnosis
Renal Insufficiency, Chronic*/drug therapy
Osteoporosis, Postmenopausal*/chemically induced
Humans ; Female ; Denosumab/adverse effects ; Calcium ; Bone Density ; Vitamin D ; Calcium Carbonate ; Republic of Korea
Czasopismo naukowe
Tytuł:
The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare.
Autorzy:
Liu Y; University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: .
Arora T; Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, USA.
Zhang J; University of Alabama at Birmingham, Birmingham, AL, USA.
Sodhi SK; Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, USA.
Xie F; Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, USA.
Curtis JR; University of Alabama at Birmingham, Birmingham, AL, USA; Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, USA.
Pokaż więcej
Źródło:
Bone [Bone] 2024 Jan; Vol. 178, pp. 116954. Date of Electronic Publication: 2023 Nov 05.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
COVID-19*
Osteoporosis, Postmenopausal*/drug therapy
United States ; Humans ; Female ; Aged ; Bone Density ; Postmenopause ; Communicable Disease Control ; Medicare
Czasopismo naukowe
Tytuł:
Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.
Autorzy:
Miyauchi A; Miyauchi Medical Center, Osaka, Japan.
Hamaya E; Amgen K.K., Midtown Tower 9-7-1 Akasaka, Minato-ku, Tokyo, 107-6239, Japan. .
Shimauchi J; Amgen K.K., Midtown Tower 9-7-1 Akasaka, Minato-ku, Tokyo, 107-6239, Japan.
Yoshinaga Y; Amgen K.K., Midtown Tower 9-7-1 Akasaka, Minato-ku, Tokyo, 107-6239, Japan.
Nishi K; Amgen K.K., Midtown Tower 9-7-1 Akasaka, Minato-ku, Tokyo, 107-6239, Japan.
Pokaż więcej
Źródło:
Journal of bone and mineral metabolism [J Bone Miner Metab] 2024 Jan; Vol. 42 (1), pp. 77-89. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Osteoporosis*/complications
Osteoporosis*/drug therapy
Osteoporosis*/chemically induced
Fractures, Bone*/drug therapy
Fractures, Bone*/prevention & control
Fractures, Bone*/chemically induced
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Antibodies, Monoclonal*
Humans ; Female ; Aged ; Aged, 80 and over ; Male ; Teriparatide/therapeutic use ; Japan ; Bone Density ; Diphosphonates/therapeutic use ; Lumbar Vertebrae ; Denosumab/pharmacology ; Denosumab/therapeutic use
Czasopismo naukowe
Tytuł:
What is the role of risedronate in the primary and secondary prevention of fractures associated with osteoporosis in postmenopausal women? A Cochrane review summary with commentary.
Autorzy:
Arman S; Department of Physical Medicine and Rehabilitation, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Pokaż więcej
Źródło:
International journal of rheumatic diseases [Int J Rheum Dis] 2024 Jan; Vol. 27 (1), pp. e14940. Date of Electronic Publication: 2023 Oct 30.
Typ publikacji:
Journal Article
MeSH Terms:
Fractures, Bone*/complications
Fractures, Bone*/prevention & control
Osteoporosis*/diagnosis
Osteoporosis*/drug therapy
Osteoporosis*/prevention & control
Osteoporosis, Postmenopausal*/diagnosis
Osteoporosis, Postmenopausal*/drug therapy
Osteoporosis, Postmenopausal*/prevention & control
Bone Density Conservation Agents*/adverse effects
Female ; Humans ; Risedronic Acid/adverse effects ; Secondary Prevention ; Postmenopause ; Bone Density
Czasopismo naukowe
Tytuł:
Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Autorzy:
Clifton Goldney D; Instituto de Diagnostico E Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina.
Pelegrin C; Instituto de Diagnostico E Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina.
Jerkovich F; Instituto de Diagnostico E Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina.
Longobardi V; Instituto de Diagnostico E Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina.; Cátedra de Osteología Y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, Argentina.
Gonzalez Rodriguez E; Interdisciplinary Center for Bone Diseases, Rheumatology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Zanchetta MB; Instituto de Diagnostico E Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina. .; Cátedra de Osteología Y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, Argentina. .
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2024 Jan; Vol. 35 (1), pp. 165-171. Date of Electronic Publication: 2023 Sep 13.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Fractures, Bone*/epidemiology
Spinal Fractures*/complications
Osteoporosis, Postmenopausal*/complications
Osteoporosis, Postmenopausal*/drug therapy
Female ; Humans ; Denosumab/adverse effects ; Teriparatide/therapeutic use ; Zoledronic Acid/therapeutic use ; Follow-Up Studies ; Bone Density
Czasopismo naukowe
Tytuł:
Sustained hypophosphatemia after denosumab in a patient on hemodialysis.
Autorzy:
Almodares AAS; Department of Medicine 1 - Endocrinology- Nephrology and Cardiology, Holbæk Hospital, Holbæk, Denmark.
Elder GJ; Skeletal Biology Program, Garvan Institute of Medical Research, Australia; Department of Renal Medicine, Westmead Hospital, Sydney, Australia.
Abrahamsen B; Department of Medicine 1 - Endocrinology- Nephrology and Cardiology, Holbæk Hospital, Holbæk, Denmark.; Open Patient Data Exploratory Network (OPEN), University of Southern Denmark, Odense, Denmark. Electronic address: .
Pokaż więcej
Źródło:
Bone [Bone] 2024 Apr; Vol. 181, pp. 117045. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Hypocalcemia*/chemically induced
Hypophosphatemia*/chemically induced
Renal Insufficiency*/chemically induced
Bone Density Conservation Agents*/adverse effects
Humans ; Male ; Aged, 80 and over ; Denosumab/adverse effects ; Renal Dialysis/adverse effects ; Phosphates ; Bone Density
Czasopismo naukowe
Tytuł:
Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management.
Autorzy:
Anastasilaki E; School of Medicine, European University of Cyprus, Nicosia, Cyprus.
Paccou J; Univ. Lille, CHU Lille, MABlab ULR 4490, Department of Rheumatology, 59000, Lille, France.
Gkastaris K; Deparment of Endocrinology and Diabetes, St Luke's Hospital, Thessaloniki, Greece.
Anastasilakis AD; Department of Endocrinology, 424 Military General Hospital, Ring Road, 564 29 N. Efkarpia, Thessaloniki, Greece. .
Pokaż więcej
Źródło:
Hormones (Athens, Greece) [Hormones (Athens)] 2023 Dec; Vol. 22 (4), pp. 611-622. Date of Electronic Publication: 2023 Sep 27.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Bone Density Conservation Agents*/pharmacology
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Osteoporosis*/prevention & control
Humans ; Bone Density ; Fractures, Bone/drug therapy ; Glucocorticoids/adverse effects ; Male ; Female
Czasopismo naukowe
Tytuł:
Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review.
Autorzy:
Zhang JY; College of Chemistry and Chemical Engineering, Zhengzhou Normal University, Zhengzhou, 450044, China.
Zhong YH; Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, 130033, China; Department of Orthopedics, The Fourth Affiliated Hospital of Guangxi Medical University/Liu-Zhou Worker's Hospital, Liuzhou, Guangxi, 545005, China.
Chen LM; Department of Orthopedics, The Fourth Affiliated Hospital of Guangxi Medical University/Liu-Zhou Worker's Hospital, Liuzhou, Guangxi, 545005, China.
Zhuo XL; Department of Orthopedics, The Fourth Affiliated Hospital of Guangxi Medical University/Liu-Zhou Worker's Hospital, Liuzhou, Guangxi, 545005, China.
Zhao LJ; The Rogel Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, United States. Electronic address: .
Wang YT; First People's Hospital of Shangqiu, Henan Province, Shangqiu, 476100, China; Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, 130033, China. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2023 Nov 05; Vol. 259, pp. 115654. Date of Electronic Publication: 2023 Jul 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Osteoporosis, Postmenopausal*/drug therapy
Osteoporosis*/drug therapy
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Female ; Humans ; Bone Density ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Selective Estrogen Receptor Modulators/pharmacology
Czasopismo naukowe
Tytuł:
Effect of denosumab on glucose metabolism in postmenopausal osteoporotic women with prediabetes: a study protocol for a 12-month multicenter, open-label, randomized controlled trial.
Autorzy:
Wang Y; Medical School of Chinese PLA, Beijing, 100853, China.; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.
Jiang Y; Medical School of Chinese PLA, Beijing, 100853, China.; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.
Li J; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.; National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, 100853, China.
Lin X; Medical School of Chinese PLA, Beijing, 100853, China.; Department of Rehabilitation, the Second Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Luo Y; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.; National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, 100853, China.
Tan S; Medical School of Chinese PLA, Beijing, 100853, China.; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.
Yang H; Medical School of Chinese PLA, Beijing, 100853, China.; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.
Gao Z; Medical School of Chinese PLA, Beijing, 100853, China.; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.
Cui X; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.; National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, 100853, China.
Yin P; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.; National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, 100853, China.
Kong D; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.
Gao Y; Department of Nursing, the First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Cheng Y; Department of Endocrinology, Chinese PLA General Hospital, Beijing, 100853, China.
Zhang L; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China.; National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, 100853, China.
Tang P; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China. .; National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, 100853, China. .
Lyu H; Department of Orthopedics, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, People's Republic of China. .; National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, Beijing, 100853, China. .
Pokaż więcej
Źródło:
Trials [Trials] 2023 Dec 18; Vol. 24 (1), pp. 812. Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/diagnosis
Diabetes Mellitus, Type 2*/drug therapy
Osteoporosis*/diagnosis
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/diagnosis
Osteoporosis, Postmenopausal*/drug therapy
Prediabetic State*/diagnosis
Prediabetic State*/drug therapy
Female ; Humans ; Blood Glucose ; Bone Density ; Denosumab/pharmacology ; Glycated Hemoglobin ; Multicenter Studies as Topic ; Postmenopause ; Randomized Controlled Trials as Topic ; RANK Ligand
Czasopismo naukowe
Tytuł:
Effect of denosumab on bone mineral density in a postmenopausal osteoporotic woman with prolonged chronic mild hyponatremia.
Autorzy:
Fujishima R; Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan.; Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan.
Ushimaru S; Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan.; Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan.
Sumi H; Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan.; Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan.
Aso M; Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan.; Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan.
Akaike T; Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan.
Shiizaki K; Nephrology and Dialysis Clinic Koga, 187, Nishiushigaya, Koga, Ibaraki, 306-0233, Japan.
Tominaga N; Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan. .; Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan. .; Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, Kawasaki, Kanagawa, 214-8525, Japan. .
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2023 Dec; Vol. 34 (12), pp. 2139-2140. Date of Electronic Publication: 2023 Sep 19.
Typ publikacji:
Letter
MeSH Terms:
Hyponatremia*/chemically induced
Bone Density Conservation Agents*/adverse effects
Osteoporosis, Postmenopausal*/complications
Osteoporosis, Postmenopausal*/drug therapy
Female ; Humans ; Denosumab/adverse effects ; Bone Density ; Postmenopause
Opinia redakcyjna
Tytuł:
Efficacy of denosumab on bone metabolism and bone mineral density in renal transplant recipients: A systematic review and meta-analysis.
Autorzy:
Zhu P; Department of Internal Medicine, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, PR China.
Yang T; Department of Respiratory and Critical Care Medicine, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, PR China.
Le J; Orthopedics Department, Hangzhou TCM Hospital Affliated to Zhejiang Chinese Medical University, PR China.
Fu X; Orthopedics Department, Hangzhou TCM Hospital Affliated to Zhejiang Chinese Medical University, PR China.
Zhang L; Orthopedics Department, Hangzhou TCM Hospital Affliated to Zhejiang Chinese Medical University, PR China. Electronic address: .
Pokaż więcej
Źródło:
Transplantation reviews (Orlando, Fla.) [Transplant Rev (Orlando)] 2023 Dec; Vol. 37 (4), pp. 100793. Date of Electronic Publication: 2023 Aug 26.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Hypocalcemia*/etiology
Kidney Transplantation*/adverse effects
Humans ; Bone Density ; Denosumab/therapeutic use
Czasopismo naukowe
Tytuł:
Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades.
Autorzy:
Orhadje E; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Berg K; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Hauser B; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Ralston SH; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK. .
Pokaż więcej
Źródło:
Calcified tissue international [Calcif Tissue Int] 2023 Dec; Vol. 113 (6), pp. 591-596. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Pregnancy Complications*/drug therapy
Pregnancy Complications*/epidemiology
Venous Thromboembolism*/complications
Venous Thromboembolism*/drug therapy
Osteoporosis*/drug therapy
Osteoporosis*/epidemiology
Osteoporosis*/complications
Bone Density Conservation Agents*/therapeutic use
Fractures, Bone*/epidemiology
Fractures, Bone*/etiology
Fractures, Bone*/prevention & control
Spinal Fractures*/epidemiology
Pregnancy ; Humans ; Female ; Incidence ; Anticoagulants/therapeutic use ; Bone Density/physiology ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta.
Autorzy:
Hald JD; Department of Endocrinology and Internal Medicine, Aarhus Universitet, Aarhus, Denmark.
Keerie C; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
Weir CJ; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
Javaid MK; Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
Lam W; Centre for Genomic and Experimental Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK.
Osborne P; Brittle Bone Society, Dundee, UK.
Walsh J; Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
Langdahl BL; Department of Endocrinology and Internal Medicine, Aarhus Universitet, Aarhus, Denmark.
Ralston SH; Centre for Genomic and Experimental Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK .
Pokaż więcej
Źródło:
BMJ open [BMJ Open] 2023 Nov 22; Vol. 13 (11), pp. e078164. Date of Electronic Publication: 2023 Nov 22.
Typ publikacji:
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Osteogenesis Imperfecta*/complications
Osteogenesis Imperfecta*/drug therapy
Bone Density Conservation Agents*/therapeutic use
Fractures, Bone*/prevention & control
Fractures, Bone*/complications
Humans ; Adult ; Adolescent ; Zoledronic Acid/therapeutic use ; Teriparatide/therapeutic use ; Quality of Life ; Bone Density ; Pain/drug therapy ; Randomized Controlled Trials as Topic
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies